Ottawa, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The global stem cell therapy market is projected to grow from USD 613.7 million in 2025 to USD 768.72 million in 2026, reaching approximately USD 5.84 billion by 2035. This represents a compound annual growth rate (CAGR) of 25.26% between 2026 and 2035, according to Towards Healthcare Research & Consulting a sister firm of Precedence Research.
Request a sample of the Stem Cell Therapy Market report, including its coverage and research scope: Download Sample
Growth is being supported by increasing research into regenerative medicine, rising demand for treatments for chronic and degenerative diseases, and progress in cell processing and manufacturing. Oncology remains the leading application, while musculoskeletal disorders, neurological conditions and cardiovascular diseases offer further development opportunities.
| Market indicator | Value | |
| Market size, 2025 | USD 613.7 million | |
| Market size, 2026 | USD 768.72 million | |
| Forecast market size, 2035 | USD 5,835.53 million | |
| CAGR, 2026–2035 | 25.26 | % |
| Leading region, 2025 | North America | |
| North America market share, 2025 | 42 | % |
| Leading therapy type, 2025 | Allogeneic stem cell therapies | |
| Leading application, 2025 | Oncology | |
Market Definition
Stem cell therapy uses stem cells to repair, replace or regenerate damaged cells and tissues. These cells can develop into different specialized cell types, making them relevant to several areas of medicine.
The market includes the development, manufacturing and use of therapies based on allogeneic and autologous stem cells, hematopoietic stem cells, mesenchymal stem cells and other cell sources. Applications range from established hematopoietic stem cell transplantation to investigational approaches for neurological, cardiovascular and musculoskeletal conditions.
The commercial opportunity extends beyond therapy developers. It also includes cell processing, culture media, expansion technologies, cryopreservation, testing, quality control, specialized storage and contract manufacturing services.
Market Key Takeaways
- The market is forecast to reach USD 5.84 billion by 2035, with a 25.26% CAGR.
- Allogeneic stem cell therapies accounted for 30% of the market by therapy type in 2025.
- Oncology represented 45% of the market by therapeutic application in 2025.
- North America held a 42% regional share in 2025.
- Asia-Pacific is expected to offer significant growth opportunities.
- Autologous therapies and musculoskeletal applications are expected to attract further research and development.
- Manufacturing scale, quality standards and regulatory readiness will remain important factors in commercialization.
Arrange a discussion about report coverage, customization or research requirements @ Schedule a Meeting
Market Trends
The industry is moving from laboratory research toward more structured clinical development and manufacturing. Companies are working to improve cell isolation, expansion, differentiation, genetic modification and cryopreservation. These capabilities are important because cell-based products require consistent quality and controlled handling throughout development and delivery.
Manufacturing partnerships are becoming more important. In February 2026, Catalent and S.Biomedics announced a partnership to support development and manufacturing of TED-A9, an allogeneic pluripotent stem-cell-derived therapy being developed for Parkinson’s disease. The collaboration highlights the role of specialized CDMOs in helping developers establish GMP-ready manufacturing for later-stage clinical development.
A further development came in February 2026, when Cellcolabs and the Center for Neuromusculoskeletal Restorative Medicine at InnoHK announced a collaboration supporting a Phase I/II clinical trial of mesenchymal stem cell therapy for knee osteoarthritis. Cellcolabs is contributing GMP-grade MSCs, connecting clinical research with industrial-scale cell production.
The broader cell and gene therapy pipeline also reflects continued clinical activity. The 2026 global regulatory report from the International Society for Cell & Gene Therapy recorded 383 active clinical trials across its cell and gene therapy scope, with Phase I and II studies representing 95% of the pipeline. This figure covers the wider cell and gene therapy field and should not be interpreted as a stem-cell-only trial count.
Market Drivers, Restraints and Opportunities
| Market factor | Industry impact | Business significance |
| Rising chronic and degenerative diseases | Supports demand for new treatment approaches | Expands clinical and commercial opportunities |
| Growing clinical research | Increases development activity across disease areas | Creates demand for trial services and manufacturing partners |
| High treatment and manufacturing costs | Limits access and commercial scalability | Increases the need for process efficiency and cost control |
| Regulatory and quality requirements | Require robust safety, efficacy and manufacturing evidence | Creates opportunities for quality, compliance and testing providers |
| Advances in genomics and cell engineering | Improve the ability to develop targeted cell products | Supports differentiated therapy platforms |
| Automation and scalable production | Can improve consistency and manufacturing capacity | Creates demand for equipment, CDMOs and process technologies |
Clinical evidence remains a key driver, but promising research does not automatically translate into an approved or commercially available treatment. Developers must demonstrate safety, efficacy, manufacturing consistency and an appropriate regulatory pathway. High development costs, reimbursement uncertainty and complex logistics can also delay wider adoption.
Market Segmentations
By Therapy Type
| Segment | 2025 market share | Market position and trend | Business opportunity | |
| Allogeneic stem cell therapies | 30 | % | Largest segment; donor-derived cells support potential off-the-shelf approaches | Scalable production, donor sourcing and immune compatibility technologies |
| Hematopoietic stem cell therapies | 18 | % | Established role in blood-related disorders and transplantation | Cell collection, processing and transplant-support services |
| Mesenchymal stem cell therapies | 16 | % | Active research across inflammatory and musculoskeletal conditions | GMP-grade MSC production and clinical partnerships |
| Autologous stem cell therapies | 15 | % | Patient-derived approach with potential to reduce immune rejection | Personalized manufacturing and patient-specific logistics |
| Bone marrow, blood and umbilical cord-derived stem cells | 10 | % | Important cell sources for clinical and research applications | Collection, banking and source-specific processing |
| Adipose-derived cells | 6 | % | Alternative source attracting regenerative medicine research | Isolation, characterization and expansion technologies |
| Others | 5 | % | Includes additional cell sources and approaches | New platforms and specialized applications |
Allogeneic therapies led the market in 2025. Their potential for standardized production and treatment of multiple patients makes them commercially attractive. However, immune compatibility, safety and manufacturing controls remain important considerations. Autologous therapies offer a different value proposition through patient-specific treatment, but their production models can be more complex and costly.
By Therapeutic Application
| Segment | 2025 market share | Market position and trend | Business opportunity | |
| Oncology | 45 | % | Largest application, supported by established hematopoietic transplantation and ongoing research | Cell processing, transplant support and new oncology-focused platforms |
| Cardiovascular disorders | 20 | % | Research continues into tissue repair and cardiac regeneration | Clinical development and specialized cell-engineering platforms |
| Musculoskeletal disorders | 18 | % | Expected to offer attractive growth opportunities | Orthopedic research, MSC manufacturing and tissue engineering |
| Others | 17 | % | Includes neurological, autoimmune and other emerging indications | New clinical programs and disease-specific partnerships |
Oncology held the largest application share. Musculoskeletal disorders are an important opportunity area, supported by research into cartilage, bone, muscle and tissue repair. Neurological applications, including Parkinson’s disease, are also attracting attention as developers investigate stem-cell-derived cell products.
Submit an inquiry about dashboard access and market intelligence requirement @ Explore the Towards Healthcare Dashboard
Market Regional and Country-Level Analysis
| Region / country | 2025 market position | Key development or trend | Business opportunity | |
| North America | 42 | % | Largest regional market, supported by research infrastructure and biotechnology investment | Clinical development, manufacturing and commercialization partnerships |
| United States | Part of North America | Strong research ecosystem and regulatory oversight | Advanced therapy development, CDMOs and specialist service providers | |
| Canada | Part of North America | Research and manufacturing infrastructure continues to develop | Regenerative medicine production and academic-industry partnerships | |
| Europe | 25 | % | Established research base and advanced therapy regulatory framework | Clinical research, GMP production and cross-border collaboration |
| Asia-Pacific | 20 | % | Expanding research activity and manufacturing capabilities | Regional clinical trials, cell processing and production capacity |
| Japan | Part of Asia-Pacific | iPSC and regenerative medicine research remains a key focus | Stem-cell-derived therapies and clinical translation | |
| China | Part of Asia-Pacific | Growing biotechnology investment and clinical research | Local manufacturing, research partnerships and market development | |
| India | Part of Asia-Pacific | Expanding biotechnology research and healthcare infrastructure | Clinical research, cell-processing services and manufacturing partnerships | |
| Latin America and Middle East & Africa | 13% combined, calculated from the reported regional shares | Smaller combined share, with market development varying by country | Research partnerships, healthcare infrastructure and future market access | |
North America led the market with a 42% share in 2025. Europe accounted for 25%, while Asia-Pacific represented 20%. The remaining 13% is the combined share for Latin America and the Middle East and Africa, calculated from the reported regional figures.
The United States and Canada benefit from established research and biotechnology ecosystems. Europe offers opportunities through its research institutions and advanced therapy development framework. Asia-Pacific is an important expansion region, particularly as Japan, China, India and South Korea strengthen research, clinical development and manufacturing capabilities.
Company and Competitive Intelligence
The competitive landscape includes therapy developers, biotechnology companies, pharmaceutical firms, research organizations and specialist manufacturing providers.
| Company / organization | Area of activity | Strategic relevance |
| Astellas Pharma | Regenerative medicine and cell therapy | Development of advanced regenerative medicine programs |
| Takeda Pharmaceutical | Cell therapy and iPSC research | Partnerships and development of next-generation cell platforms |
| S.Biomedics | Stem-cell-based regenerative therapies | Development of TED-platform therapies, including TED-A9 |
| Abeona Therapeutics | Cell and gene therapy | Development of treatments for serious and rare diseases |
| Gamida Cell | Hematopoietic cell therapy | Cell-based approaches for transplantation |
| Aspen Neuroscience | Regenerative medicine | Development of cell-based approaches for neurological conditions |
| BlueRock Therapeutics | Pluripotent stem cell-derived therapies | Development of regenerative cell products |
| Cellcolabs | Mesenchymal stem cell manufacturing | GMP-grade MSC production and research collaborations |
The 2026 partnerships involving S.Biomedics and Cellcolabs show how developers are combining clinical expertise with external manufacturing capabilities. For investors and business development teams, monitoring clinical milestones, production readiness, partnerships, regulatory progress and manufacturing capacity is becoming as important as tracking company pipelines.
Emerging Market Opportunities
The next stage of market development will depend on the ability to translate clinical research into reproducible and commercially viable treatments. Key opportunity areas include allogeneic cell platforms, iPSC-derived therapies, automated cell expansion, cryopreservation, GMP manufacturing, quality testing and advanced cell characterization.
Companies that can demonstrate reliable production, consistent product quality and a clear regulatory strategy may be better positioned as more therapies move into later-stage clinical development.
How Towards Healthcare Supports Stem Cell Therapy Market Decisions
Towards Healthcare Research & Consulting provides market intelligence and customized research to help companies assess opportunities, monitor competitors and plan commercial strategies.
| Solution | What clients get | How it helps in the stem cell therapy market |
| Master Dataset | Company, product, pipeline, trial, facility, capacity, technology, supplier, partnership and investment information | Supports market mapping, business development, sourcing and competitor tracking |
| Towards Healthcare Strategic Positioning Quadrant™ | Company benchmarking, portfolio comparison, technology assessment and competitive positioning | Helps identify leading companies, emerging developers and gaps in the market |
| Interactive Dashboard | Structured market indicators, company activity, segments, regional trends and competitive developments | Makes it easier to monitor changes and compare market information over time |
| Quality & Manufacturing Intelligence | Facility locations, production capacity, manufacturing processes, suppliers and quality-related information | Supports manufacturing, procurement, operations and supply-chain decisions |
| Customized Research | Market entry studies, country assessments, customer intelligence, due diligence, technology analysis and GTM research | Helps companies assess expansion, investment, partnerships and commercialization opportunities |
Continuous Market Intelligence Updates
The stem cell therapy market changes as clinical programs advance, partnerships are announced, manufacturing facilities expand and regulatory requirements develop. Towards Healthcare can support ongoing monitoring through:
- Monthly updates: New company announcements, funding, partnerships, clinical trial activity and product developments.
- Quarterly updates: Competitor benchmarking, pipeline progress, market activity and regional developments.
- Six-monthly updates: Changes in manufacturing capacity, technology adoption, investment patterns and market positioning.
- Annual updates: Market size and forecast revisions, segment performance, country opportunities and long-term competitive analysis.
Fill out the form for relevant samples, case studies, and examples @ sales@towardshealthcare.com
Report and Research Access
- Purchase / Buy Now – Review report licensing options and proceed to purchase.
- Schedule a Meeting – Arrange a discussion about report coverage, customization or research requirements.
- Explore the Towards Healthcare Dashboard – Submit an inquiry about dashboard access and market intelligence requirements.
- Explore the Stem Cell Therapy Market Report – View the market forecast, segments, regional analysis and company coverage.
Related Reports
- Stem Cell Reconstructive Market
- Cell Therapy Market
- Cell and Gene Therapy Services Market
- U.S. Cell and Gene Therapy Market
- Autologous Cell Therapy Market
- Autologous Stem Cell and Non-Stem Cell Therapies Market
- Cell Therapy Monitoring Kits Market
- U.S. Advanced Therapy Manufacturing Market
- Cell and Gene Therapy Predictions for 2026
Partner
Connect With Us
- USA: +1 804 441 9344
- APAC: +61 485 981 310 | +91 87933 22019 | +65 3105 1271
- Europe: +44 7383 092 044
- Email: sales@towardshealthcare.com
Follow Us
